Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf221 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Todd T Brown und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents, Tenofovir. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate–emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration. clinicaltrials.gov (NCT02720094).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Institute of HIV Research and Innovation, Bangkok, Thailand.
- Department of Infectious and Parasitic Diseases, University of Sao Paulo, Sao Paolo, Brazil.
- Astra Zeneca, Gaithersburg, Maryland, USA.
- Gilead Sciences, Foster City, California, USA.
ORCID-Profile: Todd T Brown, Ricardo Vasconcelos, Brett Hanscom, Raphael J Landovitz
Förderung
- NIAID NIH HHS
Zitieren
APA
Brown, T. T., Arao, R. F., Warsi, M., Phanuphak, N., Vasconcelos, R., Oyedele, T., Sullivan, P. A., Hanscom, B., Rooney, J. F., Rinehart, A. R., McCauley, M., Grinsztejn, B., & Landovitz, R. J. (2025). Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf221
Vancouver
Brown TT, Arao RF, Warsi M, Phanuphak N, Vasconcelos R, Oyedele T, et al. Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf221
BibTeX
@article{Brown2025,
author = {Brown, Todd T and Arao, Robert F and Warsi, Maryam and Phanuphak, Nittaya and Vasconcelos, Ricardo and Oyedele, Temitope and Sullivan, Philip A and Hanscom, Brett and Rooney, James F and Rinehart, Alex R and McCauley, Marybeth and Grinsztejn, Beatriz and Landovitz, Raphael J},
title = {Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf221}
}
EUVIMED